Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Strong showing for TAVR after 5 years in PARTNER 2A

Key clinical point: In the longest follow-up for intermediate-risk patients with severe aortic stenosis, transcatheter and surgical aortic valve replacement had similar rates of death or disabling stroke.

Major finding: The primary endpoint of death and disabling stroke at 5 years was 47.9% in the TAVR group and 43.4% in the surgery group, a difference that did not reach statistical significance (HR, 1.09; P = .21).

Study details: An analysis of PARTNER 2A, a randomized trial of 2,032 intermediate-risk patients with severe AS who were assigned to either TAVR or SAVR at 57 centers.

Disclosures: The PARTNER 2A study was funded by Edwards Lifesciences. Dr. Thourani has received grant or research support from and participation in steering committees for Edwards Lifesciences, Abbott Vascular, Boston Scientific, Gore Vascular, JenaValve, and Cryolife.

Citation:

Thourani V et al. TCT 2019. Late-breaking trials session.